Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Innoviva, Inc. Director's Dealing 2014

Feb 25, 2014

32090_dirs_2014-02-24_fadcb83d-4b73-45da-9d99-437798c6e2ff.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2014-02-20

Reporting Person: Mammen Mathai (SVP, Research & Early Clin Dev)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-02-20 Common Stock F 4307 $39.98 Disposed 182316 Direct